Eversana partners on migraine treatment launch
Zosano Pharma Corp. has tapped life-sciences solutions firm Eversana to help commercialize and distribute Qtrypta to the US market. The transdermal microneedle product is a candidate for the acute treatment of migrane.
In March 2020, the US Food and Drug Administration (FDA) gave its thumbs up on a New Drug Application for Qtrypta, granting the treatment a Prescription Drug User Fee Act (PDUFA) goal date of October 20 of this year; if ultimately approved, the drug would be the first microneedle patch product indicated for acute treatment of migraine.
Zosano Pharma president and CEO Steven Lo said the company believes the drug holds significant potential for patients suffering from migraine and looks forward to the partnership with Eversana.
“This collaboration enables us to access a comprehensive commercial organization without the significant expense and time that would have been required to build our own infrastructure,” Lo said. “We and Eversana have been working closely to ensure our commercialization strategies are aligned to provide appropriate resources to enable patients to access Qtrypta if approved.”
Eversana reportedly will leverage its commercial execution resources for marketing, market access, distribution, sales force deployment, reimbursement, and patient adherence support services. The company plans to make use of its integrated data and analytics platform to analyze fully integrated data, predict product and patient needs, and inform commercial activities at launch of Qtrypta, and beyond.
Jim Lang, Eversana’s CEO, said the company offers “comprehensive commercial services” for pharma firms like Zosano.
“Our partnership with Zosano puts the patient first by supporting broad market access, efficient distribution and comprehensive patient support services. We will work closely with Zosano on each stage of the product launch and roll-out,” he said.
According to the terms of the five-year agreement, the two firms will collaborate on various activities for the term, pursuant to an anticipated $250m commercialization budget for Qtrypta. Zosano will maintain ownership of the Qtrypta New Drug Application, in addition to all legal, regulatory, and manufacturing responsibilities for the product.
Additionally, Eversana reportedly will receive exclusive right to conduct agreed commercialization activities and will utilize its internal sales organization along with its other commercial capabilities for market access, marketing, distribution and patient support services for Qtrypta. The company will receive reimbursement of certain costs and an unspecified low double-digit percentage of product profits when Zosano net sales surpass certain costs incurred by the parties pursuant to the commercialization budget.
